CONCEPT MIA-SYNDROME AND SYSTEMIC INFLAMMATION IN END STAGE RENAL DISEASE
https://doi.org/10.24884/1561-6274-2009-13-4-64-69
Abstract
THE AIM. Comparative analysis of the manifestations of chronic systemic inflammation (CSI) and MIA-syndrome (malnutrition-inflammation-atherosclerosis syndrome) in patients with end stage renal disease (ESRD). PATIENTS AND METHODS. The study included 40 patients with ESRD with and without MIA-syndrome and two control groups (50 and 22 people respectively). The presence of MIA-syndrome, determined based on levels of serum albumin and body mass index. As indicators CSI measured serum levels of C-reactive protein, interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor (TNFα), soluble IL-2 receptor, eosinophil cationic protein, D-dimers, cortisol, myoglobin, troponin, calculated integral indicators of systemic inflammatory response (coefficient and the level of reactivity). RESULTS. It was revealed that the ESRD, regardless of nosology of this condition is characterized by the development of a model of the pathological process - CSI. The absence of statistically significant differences for most parameters CSI of patients with absence and presence of MIA-syndrome questions the fact of the greater severity of the typical model of the pathological process in the latter. In favor of this is the evidence of the lack of correlation between markers MIA-syndrome and indicators CSI. CONCLUSION. ESRD is characterized by the development of a model of the pathological process – chronic systemic inflammation, the mechanisms which contribute to the manifestation of some specific features MIA-syndrome.
About the Authors
L. V. Solomatina
Институт иммунологии и физиологии Уральского отделения РАН
Russian Federation
Russian Federation
Yu. A. Zhuravleva
Институт иммунологии и физиологии Уральского отделения РАН
Russian Federation
Russian Federation
E. Yu. Gusev
Институт иммунологии и физиологии Уральского отделения РАН
Russian Federation
Russian Federation
References
1. Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003
2. Locatelli F, Marcelli D, Conte F et al. Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lambardo Dialisi e Trapianto. Nephrol Dial Transplant 2000; 15 [suppl 5]: 69-80
3. Foley RN, Parfrey PS, Sarnack MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [suppl 3]: 112-119
4. Shah NR, Dumler F. Hypoalbuminemia – a marker of cardiovascular disease in patients of chronic kidney disease stage II-IV. Int J Med Sci 2008; 5(6): 366-370
5. Qureshi A, Alvestrand A, Divino-Filho J et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients.J Am Soc Nephrol 2002; 13: S28-S36
6. Porazko T, Kuzniar J, Kusztal M et al. IL-8 is involved in vascular injury in end-stage renal disease patients. Nephrol Dial Transplant 2009; 24(2): 586-596
7. Stenvinkel P, Alverstrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337
8. Yao Q, Axellson J, Heimburger O et al. Systemic inflammation in dialysis patients with end-stage renal disease: causes and consequences. Minerva Urol Nephrol 2004; 56: 237-248
9. Wanner C, Metzger T. C-reactive protein-a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17[suppl 8]: 29-32
10. Foley RN, Parfrey PS, Harnett JD et al. Hypoalbuminemia, cardic morbidity and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728-736
11. Ardag I, Yilmaz Y, Kahvecioglu S et al. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term predictor of cardiovascular mortality in patients with end-stage renal disease: a 5-year prospective study. Nephron Clin Pract 2008; 108 (2): 99-105
12. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47(1):139-148
13. Dhingra R, Gona P, Nam B-N et al. C-reactive protein, inflammatory conditions and cardiovascular disease risk. Am J Med 2007; 120(12):1054-1062
14. Гусев ЕЮ, Черешнев ВА, Юрченко ЛН. Системное воспаление с позиции типового патологического процесса. Цитокины и воспаление 2007; 6 (4): 9-21
15. Гусев ЕЮ, Юрченко ЛН, Черешнев ВА и др. Методология изучения системного воспаления. Цитокины и воспаление 2008; 7 (1): 15-23
16. Гусев ЕЮ, Соломатина ЛВ, Журавлёва ЮА и др. Системная воспалительная реакция у больных с терминальной хронической почечной недостаточностью. Нефрология и диализ 2008; 10 (3-4): 248-253
17. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993; 44(1):115-119
18. Beddhu S, Kaysen GA, Yan G et al. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 721-727
19. Owen WFJr, Lew NL, Liu Y et al. The reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001-1006
20. Kalantar-Zadeh K, Kilpatrick RD, Kuwae et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 2005; 20: 1880-1888
21. Лейдерман ИН, Руднов ВА, Клейн АВ и др. Синдром гиперметаболизма – универсальное звено патогенеза критических состояний. Вестник интенсивной терапии 1997; (3): 17-23
Review
For citations:
Solomatina L.V., Zhuravleva Yu.A., Gusev E.Yu. CONCEPT MIA-SYNDROME AND SYSTEMIC INFLAMMATION IN END STAGE RENAL DISEASE. Nephrology (Saint-Petersburg). 2009;13(4):64-69. (In Russ.) https://doi.org/10.24884/1561-6274-2009-13-4-64-69
Views:
617
Email this article 